A tiered algorithm using mid-therapy ultrasound (US) response assessment and a novel gene expression signature (GES) improves the prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC): Results from the ARTEMIS trial (NCT02276443)

被引：0
|
作者：
Seth, Sahil [1 ]
Rauch, Gaiane M. [1 ]
Adrada, Beatriz [1 ]
Piwnica-Worms, Helen [1 ]
Hou, Lei [1 ]
Thompson, Alastair M. [1 ]
Symmans, William F. [1 ]
Lim, Bora [1 ]
White, Jason [1 ]
Draetta, Giulio F. [1 ]
Futreal, Andrew [1 ]
Chang, Jeffrey [1 ]
Moulder, Stacy [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD9-05
引用
收藏
页数：1
相关论文
共 9 条
  • [1] Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443)
    Seth, Sahil
    Huo, Lei
    Vasaikar, Suhas
    Rauch, Gaiane
    Lim, Bora
    White, Jason
    Adrada, Beatriz
    Piwnica-Worms, Helen
    Ueno, Naoto T.
    Thompson, Alastair Mark
    Mittendorf, Elizabeth
    Tripathy, Debashish
    Litton, Jennifer Keating
    Symmans, William Fraser
    Draetta, Giulio
    Futreal, Andrew
    Chang, Jeffrey
    Moulder, Stacy
    CANCER RESEARCH, 2020, 80 (04)
  • [2] Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443).
    Seth, Sahil
    Huo, Lei
    Rauch, Gaiane M.
    Adrada, Beatriz E.
    Piwnica-Worms, Helen
    Thompson, Alastair Mark
    Mittendorf, Elizabeth A.
    Litton, Jennifer Keating
    Symmans, William Fraser
    Draetta, Giulio Francesco
    Futreal, Andrew
    Moulder, Stacy L.
    Chang, Jeff
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)
    Abuhadra, N.
    Sun, R.
    Litton, J. K.
    Rauch, G.
    Thompson, A. M.
    Lim, B.
    Adrada, B.
    Mittendorf, E.
    Damodaran, S.
    Pitpitan, R.
    Arun, B.
    White, J.
    Ravenberg, E.
    Santiago, L.
    Sahin, A.
    Murthy, R.
    Ueno, N. T.
    Ibrahim, N.
    Moulder, S.
    Huo, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S49 - S49
  • [4] Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx)
    Gupta, Tanya
    Graf, Ryon P.
    Schrock, Alexa B.
    Madison, Russell
    Ross, Jeffrey S.
    Levy, Mia Alyce
    Quintanilha, Julia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC).
    Abuhadra, Nour
    Sun, Ryan
    Litton, Jennifer Keating
    Rauch, Gaiane M.
    Thompson, Alastair Mark
    Lim, Bora
    Adrada, Beatriz E.
    Mittendorf, Elizabeth A.
    White, Jason B.
    Ravenberg, Elizabeth
    Damodaran, Senthil
    Candelaria, Rosalind P.
    Arun, Banu
    Ueno, Naoto T.
    Santiago, Lumarie
    Murthy, Rashmi Krishna
    Ibrahim, Nuhad K.
    Symmans, William Fraser
    Moulder, Stacy L.
    Huo, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy.
    Abuhadra, Nour
    Hess, Kenneth R.
    Litton, Jennifer Keating
    Rauch, Gaiane M.
    Thompson, Alastair Mark
    Lim, Bora
    Adrada, Beatriz E.
    Mittendorf, Elizabeth A.
    Damodaran, Senthil
    Candelaria, Rosalind P.
    Arun, Banu
    Yang, Wei Tse
    Ueno, Naoto T.
    Santiago, Lumarie
    Murthy, Rashmi Krishna
    Ibrahim, Nuhad K.
    Sahin, Aysegul A.
    Symmans, William Fraser
    Moulder, Stacy L.
    Huo, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial
    Golshan, Mehra
    Wong, Stephanie M.
    Loibl, Sibylle
    Huober, Jens Bodo
    O'Shaughnessy, Joyce
    Rugo, Hope S.
    Wolmark, Norman
    Ansell, Peter
    Maag, David
    Sullivan, Danielle M.
    Metzger-Filho, Otto
    Von Minckwitz, Gunter
    Geyer, Charles E., Jr.
    Sikov, William M.
    Untch, Michael
    EJSO, 2020, 46 (02): : 223 - 228
  • [8] A model using easily evaluated clinical features to identify triple negative breast cancer (TNBC) patients (pts) with high probability of achieving pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST)
    Moulder, S.
    Adrada, B.
    Lim, B.
    Ueno, N.
    Candelaria, R.
    Rauch, G.
    Litton, J.
    Thompson, A.
    Huo, L.
    Hess, K.
    BREAST, 2019, 44 : S101 - S102
  • [9] Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial
    Wulfkuhle, J. D.
    Yau, C.
    Wolf, D. M.
    Gallagher, R. I.
    Deng, J.
    Brown-Swigart, L.
    Hirst, G.
    Rugo, H.
    Olopade, O. I.
    Esserman, L.
    Berry, D.
    van't Veer, L.
    Petricoin, E. F.
    CANCER RESEARCH, 2016, 76
1